ARTICLE | Company News

Clinuvel, Biotech Lab Singapore deal

November 17, 2014 8:00 AM UTC

Clinuvel and Biotech Lab Singapore formed a JV to develop pediatric formulations of Clinuvel's Scenesse afamelanotide ( CUV1647) and CUV9900. Clinuvel will lead and oversee regulatory development, while Biotech Lab Singapore will manage chemistry and formulation development in Asia. The JV will own IP rights to the pediatric formulations. The JV -- to be named Vallaurix Pte. Ltd. -- will develop pediatric afamelanotide to treat erythropoietic protoporphyria (EPP) and pediatric CUV9900 as a complementary therapy in photodermatoses and depigmentation disorders such as vitiligo. Clinuvel will have a majority interest in the partnership, but the company said financial terms were not disclosed. ...